Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904998 | 1.00 | LMNA (0.56) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL4509621 | 1.00 | LMNA (0.56) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL3696275 | 0.93 | LMNA (0.61) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL11683165 | 0.93 | LMNA (0.61) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL11681508 | 0.91 | LMNA (0.56) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL1296360 | 0.91 | — | — | |
| Bromide SCHEMBL28303227 | 0.88 | PTPN1 (0.41) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL1455243 | 0.84 | PTPN1 (0.40) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL1455188 | 0.84 | PTPN1 (0.40) | LMNAPTPN1BLMMEN1CYP3A4 | |
| SCHEMBL1906086 | 0.84 | PTPN1 (0.40) | LMNAPTPN1BLMMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724996-B2 | Synthesis of intermediates for the preparation of alpha-tocopherol | DSM IP ASSETS B.V. (NL) | 2023-08-15 | — | — | US | disclosed |
| EP-3652162-B1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS BV (NL) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023016459-A1 | NOVEL ORGANIC ALKOXIDE AGGLOMERATE, AND PREPARATION METHOD THEREFOR AND APPLICATION AND THEREOF | 上海科技大学 | 2023-02-16 | — | — | WO | disclosed |
| US-11471533-B2 | Compound usable as cationic lipid | KYOWA KIRIN CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| EP-3521270-B1 | CATIONIC LIPID COMPOUND | KYOWA KIRIN CO LTD (JP) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021238947-A1 | METHOD FOR PREPARING QUINONE COMPOUND | 上海科技大学 | 2021-12-02 | — | — | WO | disclosed |
| US-20210300886-A1 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS BV (NL) | 2021-09-30 | — | — | US | disclosed |
| US-20210275672-A1 | COMPOUND USABLE AS CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20200131145-A1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS B.V. (NL) | 2020-04-30 | — | — | US | disclosed |
| EP-3521270-A1 | CATIONIC LIPID COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-6133471-A | Process for producing chromans | KURARAY CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6130341-A | Process for producing chromans | KURARAY CO., LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| EP-0645383-B1 | Process for producing chromanes | KURARAY CO (JP) | 1999-03-24 | — | — | EP | disclosed |
| EP-0891974-A1 | Process for producing chromans | KURARAY CO., LTD. (JP) | 1999-01-20 | — | — | EP | disclosed |
| US-5495026-A | Process for producing chroman | KURARAY COMPANY LTD. (JP) | 1996-02-27 | — | — | US | disclosed |
| EP-0645383-A1 | Process for producing chroman | KURARAY CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
| EP-0310005-B1 | Process for modifying the microbial cleansing of soil contaminated with hydrocarbons, in particular with mineral oils, by microbial oxidation | WINTERSHALL AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| US-4888275-A | DETERMINATION OF CARBOHYDRATE ANTIGEN | PHARMACIA AB, S-751 82 UPPSALA (CH) | 1989-12-19 | — | — | US | disclosed |
| EP-0310005-A1 | Process for modifying the microbial cleansing of soil contaminated with hydrocarbons, in particular with mineral oils, by microbial oxidation | WINTERSHALL AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | disclosed |
| US-3946081-A | OXIDATION CATALYSTS, GROUP V, VI, OR VII OXIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300886-A1 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | TTPA, DHPS, SQLE | LMNA 1425/4885PTPN1 4639/4885BLM 3409/4885 |
| US-20200131145-A1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | TTPA, VKORC1, SQLE | LMNA 1413/4885PTPN1 4761/4885BLM 3636/4885 |
| US-11471533-B2 | Compound usable as cationic lipid | NPC1L1, PLIN1, PLIN5 | LMNA 278/4885PTPN1 4533/4885BLM 1287/4885 |
| US-11724996-B2 | Synthesis of intermediates for the preparation of alpha-tocopherol | TTPA, DHPS, SQLE | LMNA 1425/4885PTPN1 4639/4885BLM 3409/4885 |
| US-20210275672-A1 | COMPOUND USABLE AS CATIONIC LIPID | NPC1L1, PLIN1, PLIN5 | LMNA 278/4885PTPN1 4533/4885BLM 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.